News
InSyBio joins Loyal VC program and receives initial investment
InSyBio has joined the Loyal VC program which includes an initial investment from the Toronto, Canada based international fund and provides InSyBio with access to Loyal VC’s global network of over 400 advisors and experienced entrepreneurs, accelerator leaders, advisors, angels and venture investors. InSyBio will benefit from active business development support and guidance as well as having… Continue reading→
Precision Chronic Pain Treatment Tool: a first-of-its-kind tool for personalizing treatment of Chronic Pain Patients
In an effort to find a better alternative to the traditionally prescribed opioid analgesics, InSyBio worked in collaboration with Clarity Science LLC and developed a machine learning-based tool for predicting the response of chronic pain patients to 4 different non-opioid pain treatment formulations. This tool is capitalizing on InSyBio’s unique machine learning technology to develop… Continue reading→
InSyBio DNA-seq has been launched allowing the discovery of genomic variants and their integration with other omics biomarkers
A new tool has been integrated in InSyBio Suite (InSyBio DNA-seq) which enables the fast and accurate pre-processing and analysis of DNA-sequencing data by non-bioinformatics experts with optimized pipelines. This tool includes the following functionalities: InSyBio’s CEO, Labros Digonis, stated that“Genomics is the area contributing more than 70% of the biomarkers used in clinical practice nowadays, being… Continue reading→
JSS forms strategic partnership with InSyBio to pioneer precision medicine innovation in clinical trials
In a bold approach to revolutionize a vital part of the pharmaceutical/nutraceutical industry and change the stagnant norm that is the clinical trial process, JSS Medical Research Inc. has strategically partnered with InSyBio, a leading bioinformatics company, to drive desperately needed transformation. With credit to Axios Investments Corporation for facilitating the partnership, InSyBio and JSS… Continue reading→
InSyBio Suite V2.6 has been launched offering a unique user experience and allowing exploration of the “dark matter” transcriptomics datasets
The new version of InSyBio Suite enables the fast and accurate analysis of omics data by non-bioinformatics experts empowered with novel techniques to explore the dark matter of the transcriptomics data. This new version: InSyBio Suite version 2.6 has been officially launched as of Friday November 15th 2019. The Chief Scientific Officer of InSyBio, Dr. Seferina Mavroudi, stated… Continue reading→
InSyBio showcasing its breakthrough technology in investment Community of Texas
ISyBio is showcasing as one of 7 prestigious companies during The International Accelerator’s Demo Day taking place October 22nd, 2019 at 4:30pm. As one of the leading companies in targeted biomarker discovery, InSyBio is revolutionizing both the medical and food/nutrition research fields. We drive innovation in both clinical trials and drug discovery through our proprietary analysis… Continue reading→
Novel Stroke biosignature and machine learning model identified for greatest diagnostic accuracy through blood samples
In a close collaboration with a prestigious Austin, TX medical center, InSyBio applied its proprietary technology to identify targeted biomarkers to provide an unbiased, non-interventive diagnostic method for Stroke. This is incredibly important when making clinical decisions in such a time-sensitive situation as stroke, where blood biomarkers could aid in faster diagnosis and treatment. Classifying… Continue reading→
Team VIRTUOUS: InSyBio pioneering precision nutrition through European funded project
In conjunction with a prestigious team of researchers and industry, InSyBio has been awarded funding under the Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE) for precision nutrition. Benefiting industry and academia worldwide, the team will work to design an intelligent “virtual tongue” (VIRTUOUS) capable of taste prediction. Through the integration of drug discovery techniques,… Continue reading→
InSyBio taking steps to help tackle the opioid crisis through precision medicine
In an effort to find a better alternative to the traditionally prescribed opioid analgesics, InSyBio worked in collaboration with Clarity Science and the OPERA study (Optimizing Patient Experience and Response to Topical Analgesics) to utilize advanced machine learning methods to not only predict patient response to treatment but also to stratify chronic pain patients into individuals who will… Continue reading→
InSyBio awarded on Ignite Ideas program organised by Nestle Hellas
InSyBio has been recently awarded for its superior performance in the context of the Ignite Ideas program (https://igniteideas.gr/en/) which was organised by Nestle Hellas. InSyBio has participated in this program, with its revolutionary idea of personalizing the coffee blend and type selection combining input from a saliva test and responses to questionnaires in order to… Continue reading→